ABSTRACT

Introduction

Nonsmall cell lung cancer (NSCLC) accounts for 80–85% of the cases of lung cancer. The conventional therapeutic effective dosage forms used to treat NSCLC are associated with rigid administration schedules, adverse effects, and may be associated with acquired resistance to therapy. Nanocarriers may provide a suitable alternative to regular formulations to overcome inherent drawbacks and provide better treatment modalities for the patient.

Areas covered

The article explores the application of drug loaded nanocarriers for lung cancer treatment. Drug-loaded nanocarriers can be modified to achieve controlled delivery at the desired tumor infested site. The type of nanocarriers employed are diverse based on polymers, liposomes, metals and a combination of two or more different base materials (hybrids). These may be designed for systemic delivery or local delivery to the lung compartment (via inhalation).

Expert opinion

Nanocarriers can improve pharmacokinetics of the drug payload by improving its delivery to the desired location and can reduce associated systemic toxicities. Through nanocarriers, a wide variety of therapeutics can be administered and targeted to the cancerous site. Some examples of the utilities of nanocarriers are codelivery of drugs, gene delivery, and delivery of other biologics. Overall, the nanocarriers have promising potential in improving therapeutic efficacy of drugs used in NSCLC.

中文翻译：

---

非小细胞肺癌的靶向药物治疗：临床意义和可能的解决方案-第二部分（纳米载体的作用）

摘要

介绍

非小细胞肺癌（NSCLC）占肺癌病例的80–85％。用于治疗NSCLC的常规治疗有效剂型与严格的给药方案，不良反应有关，并且可能与获得的对治疗的抗性有关。纳米载体可为常规制剂提供合适的替代品，以克服固有的缺点并为患者提供更好的治疗方式。

覆盖区域

本文探讨了载药纳米载体在肺癌治疗中的应用。可以修饰载有药物的纳米载体，以在所需的肿瘤感染部位实现受控的递送。所使用的纳米载体的类型基于聚合物，脂质体，金属以及两种或更多种不同基础材料（混合物）的组合而不同。这些可以设计用于全身递送或局部递送到肺腔（通过吸入）。

专家意见

纳米载体可以通过改善药物有效载荷向所需位置的输送来改善药物有效载荷的药代动力学，并可以降低相关的全身毒性。通过纳米载体，可以施用多种治疗剂并将其靶向癌部位。纳米载体的效用的一些例子是药物的代码传递，基因传递和其他生物制剂的传递。总体而言，纳米载体在改善NSCLC中使用的药物的治疗功效方面具有广阔的潜力。